Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors

NCT04911907 | Unknown Phase 2

• 1 other identifier: BG01-2002
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 3

Brief Summary

This trial is an open, two-stage, multi-center, phase II clinical trial to evaluate the efficacy and safety of Utidelone in advanced solid tumors (excluding breast cancer, lung cancer, and colorectal cancer) that have failed standard of treatment or were unable to perform standard treatment. This trial is divided into 2 stages, screening stage and expansion stage. In the screening stage, 10 patients were enrolled for each tumor type(including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors). Based on the results of the tumor type screening stage, the sponsor and the main investigator will have a discussion and have the alignment of tumor types to enter the expansion stage. The expansion stage will refine the inclusion / exclusion criteria and may adjust the treatment plan based on the tumor type and the combination drug selection. A total of 30-50 patients (including patients enrolled in the screening stage) were enrolled in each specified tumor type during the expansion stage.

Conditions

Solid Tumor

Outcome Measures

Primary Outcomes (1)

• Tumor response to utidelone treatment

  Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR) ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.

  12 months from first study treatment

Secondary Outcomes (3)

• Clinical benefit rate (CBR)

  12 months from first study treatment

• Progression free survival (PFS)

  18 months from first study treatment

• Safety profile associated with utidelone injection

  18 months from first study treatment

Study Arms (7)

Squamous cell carcinoma of head and neck: Utidelone Injection

EXPERIMENTAL

Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy

Drug: utidelone injection

Esophageal cancer: Utidelone injection

EXPERIMENTAL

Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.

Drug: utidelone injection

Stomach cancer: Utidelone injection

EXPERIMENTAL

Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.

Drug: utidelone injection

Pancreatic cancer: Utidelone Injection

EXPERIMENTAL

Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.

Drug: utidelone injection

Ovarian cancer: Utidelone Injection

EXPERIMENTAL

Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.

Drug: utidelone injection

Cholangiocarcinoma: Utidelone

EXPERIMENTAL

Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy

Drug: utidelone injection

Other solid tumors: Utidelone Injection

EXPERIMENTAL

Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy

Drug: utidelone injection

Interventions

utidelone injection DRUG

Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Cholangiocarcinoma: Utidelone; Esophageal cancer: Utidelone injection; Other solid tumors: Utidelone Injection; Ovarian cancer: Utidelone Injection; Pancreatic cancer: Utidelone Injection; Squamous cell carcinoma of head and neck: Utidelone Injection; Stomach cancer: Utidelone injection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically documented locally-advanced and/or metastatic solid malignancy (including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors) that is incurable, and has failed prior standard therapy or for which standard therapy is not appropriate.
• Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
• Age 18 -70 years old
• ECOG performance status of 0-1
• Life expectancy≥ 3 months
• Basically normal results from routine blood test within 1 week prior to enrollment
• Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L
• Hemoglobin \>= 9 g/dL
• Platelets \>= 80 x 10\^9/L
• Basically normal liver and renal functions within 1 week prior to enrollment
• total bilirubin =\< 1.5 x ULN with direct bilirubin within normal range
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (ALT and AST =\< 5 x ULN is acceptable if liver metastases are present)
• Creatinine clearance\>=50 ml/min
• Women and men of childbearing potential must agree to take effective contraceptive measures during the study and within six months after the last treatment. Female patients must have negative urinary pregnancy test within 7 days before the first treatment (postmenopausal women must have no menstruation for at least 12 months before they are considered unable to conceive)
• Patients who give written informed consent with good compliance.

You may not qualify if:

• Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks prior to enrollment while participating in this trial, except for the following items:
• Nitrosourea or mitomycin C is within 6 weeks before the first dosage of the study drug;
• Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first use of the study drug or 5 half-life periods of the drug (whichever is longer);
• The traditional Chinese medicine with anti-tumor indication is within 2 weeks before the first use of the research medicine.
• Received other unlaunched clinical research drugs or treatment within 4 weeks before the first dosage of the research drug.
• Have undergone major organ surgery (excluding needle biopsy) or experienced significant trauma within 4 weeks prior to the first dosage of study drug, or require elective surgery during the trial period.
• Symptomatic peripheral neuropathy CTCAE 5.0 grade evaluation ≥ grade 2
• With severe allergies to castor oil, or have had serious adverse reactions with anti-microtubule drugs in the past
• Patients of pregnancy or breast feeding
• Patients with AEs caused by any previous treatment (including systemic and local treatment) that have not yet restored to GRADE 1 (excluding hair loss)
• Patient with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Patients with active infections and currently need systemic anti-infective treatment
• Patient with immunodeficiency, including a positive HIV antibody test.
• Patients with history of active hepatitis B (hepatitis B virus titer\> ULN), allow prophylactic antiviral treatment other than interferon; have a history of hepatitis C virus infection (hepatitis C antibody positive).
• Patients with history of serious cardiovascular and cerebrovascular diseases.

Sponsors & Collaborators

• Beijing Biostar Pharmaceuticals Co., Ltd.: lead
• Chengdu Biostar Pharmaceuticals: collaborator

Study Sites (3)

Luhe Hospital, Capital Medical University

Beijing, China

RECRUITING

Obstetrics and Gynecology Hospital, Capital Medical University

Beijing, China

RECRUITING

Shanghai East Hospital of Tongji University

Shanghai, China

RECRUITING

Study Officials

• JIN LI, MD

  Shanghai Tongji University Affiliated Oriental Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

RONGGUO QIU, PhD

CONTACT

01186-5631-5388; rqiu2001@yahoo.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 30, 2021
• First Posted: June 3, 2021
• Study Start: January 22, 2021
• Primary Completion: March 15, 2024
• Study Completion: December 30, 2024
• Last Updated: November 8, 2023

Record last verified: 2023-01

Locations

CN (3)